Rezvan Ebrahimi
1 
, Sanam Saeifar
2 , Yasaman Vahdani
3* , Nahid Moradi
1 1 Nickan Research Institute, Isfahan, Iran.
2 Buchmann Institute for Molecular Life Sciences (BMLS), Cluster of Excellence, Frankfurt am Main, Frankfurt Macromolecular Complexes (CEF-MC), Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
3 Department of Biochemistry and Molecular Medicine, University of Montreal, Canada.
Abstract
Introduction: Pieces of evidence indicate a relationship between breast cancer and type 2 diabetes (T2D) which is a potential risk factor for breast cancer development and progression. Hyperinsulinemia, insulin resistance, chronic inflammation, inflammatory cytokines, and hormonal factors are possible explanations for this association. T2D may also affect the breast cancer treatment course. Neoplastic cells are more chemo-resistant, and chemotherapy adverse effects are more prominent in patients with diabetes and breast cancer at the same time. Diabetic nephropathy is one of the T2D complications that should be considered prior to choosing a therapeutic protocol for breast cancer patients. Hence, collaboration between oncologists, endocrinologists, and nephrologists is essential to provide comprehensive care for T2D and breast cancer patients.